Comparative Pharmacology
Head-to-head clinical analysis: ENPRESSE 21 versus NORQUEST FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENPRESSE 21 versus NORQUEST FE.
ENPRESSE-21 vs NORQUEST FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive; suppresses gonadotropin release via estrogen-progestin negative feedback, preventing ovulation; alters cervical mucus and endometrial lining to inhibit sperm penetration and implantation.
NORQUEST FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Norethindrone induces progestational changes in the endometrium, increasing cervical mucus viscosity, and also inhibits ovulation.
ENPRESSE-21 (ethinyl estradiol/norethindrone acetate) is an oral contraceptive. One tablet (0.035 mg ethinyl estradiol/0.5 mg norethindrone acetate) by mouth once daily for 21 days, followed by 7 placebo days.
One tablet orally once daily, each tablet containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (21 active tablets) followed by 7 ferrous fumarate tablets.
None Documented
None Documented
Terminal elimination half-life is 8-10 hours; this supports once-daily dosing and reaches steady state within 2-3 days.
Terminal half-life: 6-8 hours. Clinical context: Supports once-daily dosing with sustained therapeutic effect.
Renal excretion of unchanged drug accounts for approximately 30-40% of the dose; hepatic metabolism accounts for the remainder, with metabolites eliminated in bile and feces.
Renal: 80% (50% unchanged, 30% as metabolites); Fecal: 19%; Biliary: <1%
Category C
Category C
Oral Contraceptive
Oral Contraceptive